Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIK066 in overweight and obese women with polycystic ovary syndrome
2017-001373-16Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polycystic ovary syndrome (PCOS) comparing LIK066 50 mg with Placebo (2 arms). Primary endpoint: Change in average morning fasting free testosterone blood concentrations from baseline. Started Jun 2017; status: completed.
02
Drugs
licogliflozin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on 2017-001373-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001373-16.